Vol. 2, Issue 1, Part A (2025)

Plant-based compounds have long been central to traditional medicine and have in recent decades drawn growing interest in modern pharmacology. Yet despite their well-documented therapeutic promise, many phytoconstituents such as curcumin from Curcuma longa, flavonoids like quercetin and naringenin, and alkaloids such as berberine and camptothecin face one persistent obstacle: poor bioavailability. These compounds often exhibit low solubility, rapid metabolism, and limited permeability across the gastrointestinal tract, restricting their therapeutic effectiveness in vivo. Nanotechnology has emerged as a transformative approach in phytopharmacology and phytomedicine, offering a sophisticated toolkit for addressing these challenges. By reducing particle size to the nanoscale, manipulating interfacial properties, and employing innovative carrier systems such as liposomes, polymeric nanoparticles, nanoemulsions, solid lipid nanoparticles, and self-emulsifying drug delivery systems, researchers have been able to significantly improve absorption, stability, and therapeutic action of these phytochemicals.
This paper explores the mechanistic basis of poor bioavailability in phytoconstituents and details how nanotechnology provides solutions that are both scientifically rigorous and clinically meaningful. Special emphasis is placed on curcumin, flavonoids, and alkaloids, which together represent some of the most widely studied yet challenging plant-derived compounds. Case studies from experimental and clinical research highlight how carefully designed nanosystems not only improve pharmacokinetic parameters but also strengthen pharmacodynamic outcomes. The broader implications of these findings extend beyond laboratory science, raising questions about regulation, large-scale manufacturing, safety, and the practical future of phytomedicines in global healthcare. In offering a synthesis of scientific advances and translational insights, this review argues that nanotechnology does not merely enhance bioavailability but redefines the clinical possibilities of phytopharmacology itself.